Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

Broker Warrant Exercise

25 Jul 2025 07:00

RNS Number : 4893S
Mast Energy Developments PLC
25 July 2025
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

('MED' or 'the Company')

 

Dated: 25 July 2025

 

MAST Energy Developments PLC

 

Exercise of Historic Broker Warrants, Issue of Equity & TVR

 

Mast Energy Developments PLC ("MED" or "the Company"), the UK-based multi-asset owner, developer, and operator in the rapidly growing Flexible Generation Power market, announces that it has received notices of exercise for a total of 243,750 new ordinary MED shares at the exercise price of £0.08 (the "Broker Warrant Shares"). The broker warrants were historically issued to nominees of Novum Securities Limited on 29 May 2024, the details of which are contained in the Company's RNS announcement dated 7 May 2024. The price and number of warrants were re-stated as part of the Company's recent share capital consolidation and re-admission of its ordinary share capital, effective 14 July 2025.

 

Total Voting Rights

Application will be made for the admission of the 243,750 Broker Warrant Shares to trading on the LSE ("Admission") pursuant to the authorities approved by shareholders at the General Meeting held on 8 July 2025. The Shares will rank pari passu with the existing ordinary shares and it is expected that Admission will become effective at 8.00 a.m. on 30 July 2025.

 

Following Admission, the Company's issued share capital will consist of 13,248,927 ordinary shares with voting rights. MED  does not hold any ordinary shares in treasury. This figure of 13,248,927 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they require to notify their interest in, or a change to their interest in, the share capital of the Company under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Following Admission, the beneficial holding of Paul Venter, non-executive director and chairman of the Company,  will change from 15.06% to 14.79% interest in the issued share capital of the Company.

 

 

Stay up to date with MED's latest news and updates by joining our emailing list and social media channels, as follows:

 

MED general enquiries - https://www.med.energy/contact

MED email alerts - https://www.med.energy/rnsannoucements-1

MED LinkedIn page - https://uk.linkedin.com/company/mast-energy-developments-plc

MED X (formerly Twitter) handle - @mastplc

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Pieter Krügel

info@med.energy

Mast Energy

Developments PLC

CEO

Guy Wheatley, CFA

+44 (0)74 9398 9014

Fortified Securities

Corporate Broker

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEDFLLEISEIW
Date   Source Headline
19th Oct 20227:00 amRNSPyebridge Trading Update
5th Oct 20227:00 amRNSMED Acquires two Projects and Secures Funding
13th Sep 20222:05 pmRNSSecond Price Monitoring Extn
13th Sep 20222:00 pmRNSPrice Monitoring Extension
23rd Aug 20227:00 amRNSHalf-year Report
8th Aug 20229:46 amRNSTR-1: Notification of major holdings
29th Jul 20222:15 pmRNSPartial Settlement Shareholder Loan & Share Issue
13th Jul 202212:46 pmRNSAppointment of Director
5th Jul 20227:00 amRNSPyebridge Trading and Operational Update
20th May 20227:00 amRNSAppointment of Chief Executive Officer
16th May 202211:24 amRNSResults of Annual General Meeting
20th Apr 20227:00 amRNSNotice of AGM
7th Apr 20227:00 amRNSGeneral Update
31st Mar 20227:00 amRNSResults for the 15 month period ended 31 Dec 2021
24th Feb 20227:00 amRNSBordesley T-4 Capacity Market Auction Results
23rd Feb 20222:05 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20229:00 amRNSPrice Monitoring Extension
2nd Dec 20212:36 pmRNSMED Share Issue
15th Nov 20217:00 amRNSPyebridge Steady State Operation and Production
20th Oct 20217:00 amRNSTerm Sheet for Project Development Funding Signed
7th Oct 20217:00 amRNSMED Completes Acquisition of Rochdale Power Ltd
1st Oct 20217:00 amRNSNew Board Appointment
2nd Sep 20217:00 amRNSUnaudited results for the 9 months ended June 2021
16th Aug 20217:00 amRNSMED Acquires Third Standby Generation Facility
12th Aug 202112:48 pmRNSPyebridge Correction of Address Particulars
12th Aug 20217:00 amRNSMED acquires 9 MW Pyebridge Facility
30th Jun 20217:00 amRNSAppointment of Joint Broker
10th Jun 20217:00 amRNSBordesley: Construction to Commence
26th May 20219:05 amRNSHalf-year Report
21st May 20217:00 amRNSBordesley Progresses to Construction-ready Status
6th May 20217:00 amRNSOperational Update
14th Apr 20217:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.